A First-in-Human Single and Multiple Ascending Dose Study of MT-701

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Doses of MT-701 in Healthy Participants

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07396909

Enrollment

Registered

2026-02-09

Start date

2026-01-12

Completion date

2026-04-16

Last updated

2026-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Keywords

MT-701, Phase 1

Brief summary

First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-701 in healthy participants.

Detailed description

This is a first-in-human study of MT-701, a biologic therapy. The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-701 in healthy participants. The data obtained from this study will inform further development of MT-701.

Interventions

DRUGMT-701

MT-701

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Masking description

Double-Blind

Eligibility

Sex/Gender

ALL

Age

19 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

1. Male or female (of non-childbearing potential only) participants between 19 and 55 years of age (inclusive) at the time of signing informed consent. 2. Female participants must be of nonchildbearing potential, defined as postmenopausal or surgically sterile and have official documentation, at least 6 months prior to the first dose. 3. Male participants must use highly effective forms of contraception during sexual intercourse with female partners of childbearing potential. A non-vasectomized, male subject must agree to use a condom with a chemical barrier method. 4. Good general health. 5. Able to provide written informed consent and understand and comply with the requirements of the study

Exclusion criteria

1. History or presence of any clinically significant organ system disease. 2. Abnormal laboratory assessments, physical exam of ECG outside the normal range that is judged by the Investigator to be clinically significant. 3. History of alcohol or drug abuse within the past 24 months. 4. Current use or history of regular tobacco or nicotine-containing products within 3 months prior to screening. 5. Administration of any prescription drug within 21 days of study drug administration; or over-the-counter drug within 7 days of study drug administration. 6. Administration or use of any investigational drug or device within 30 days preceding the first does of study drug administration. 7. Blood donation within 60 days prior to dosing or plasma donation within 14 days prior to dosing. 8. Sensitivity to any of the study drugs, or components thereof, or drug or other allergy that in the opinion of the Investigator or Sponsor Medical Monitor, contraindicates participation in the study.

Design outcomes

Primary

Measure	Time frame	Description
Number of Subjects with non-SAEs and SAES	Up to 14 days post dose	Incidence of adverse events, clinically significant laboratory abnormalities, clinically significant electrocardiogram, vital signs, and physical examination abnormalities.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 27, 2026